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Abstract
Objective: Sulodexide is a mixture of glycosaminoglycans that may reduce proteinuria in diabetic nephropathy (DN), but its
mechanism of action and effect on renal histology is not known. We investigated the effect of sulodexide on disease
manifestations in a murine model of type I DN.
Methods: Male C57BL/6 mice were rendered diabetic with streptozotocin. After the onset of proteinuria, mice were
randomized to receive sulodexide (1 mg/kg/day) or saline for up to 12 weeks and renal function, histology and fibrosis were
examined. The effect of sulodexide on fibrogenesis in murine mesangial cells (MMC) was also investigated.
Results: Mice with DN showed progressive albuminuria and renal deterioration over time, accompanied by mesangial
expansion, PKC and ERK activation, increased renal expression of TGF-b1, fibronectin and collagen type I, III and IV, but
decreased glomerular perlecan expression. Sulodexide treatment significantly reduced albuminuria, improved renal
function, increased glomerular perlecan expression and reduced collagen type I and IV expression and ERK activation. Intra-
glomerular PKC-a activation was not affected by sulodexide treatment whereas glomerular expression of fibronectin and
collagen type III was increased. MMC stimulated with 30 mM D-glucose showed increased PKC and ERK mediated
fibronectin and collagen type III synthesis. Sulodexide alone significantly increased fibronectin and collagen type III
synthesis in a dose-dependent manner in MMC and this increase was further enhanced in the presence of 30 mM D-glucose.
Sulodexide showed a dose-dependent inhibition of 30 mM D-glucose-induced PKC-bII and ERK phosphorylation, but had
no effect on PKC-a or PKC-bI phosphorylation.
Conclusions: Our data demonstrated that while sulodexide treatment reduced proteinuria and improved renal function, it
had differential effects on signaling pathways and matrix protein synthesis in the kidney of C57BL/6 mice with DN.
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Introduction
Diabetic nephropathy (DN) is a leading cause of end-stage renal
disease in developed countries. DN is characterized by glomerular
hypertrophy, basement membrane thickening, disruption of the
glomerular permeability barrier, progressive accumulation of
glomerular matrix, culminating in glomerulosclerosis, tubulo-
interstitial fibrosis, and progressive proteinuria and deterioration
of renal function [1–4].
The extracellular matrix (ECM) plays an active role in
regulating the structure and function of adjacent cells, and
influences cell morphology, differentiation, anchorage and inter-
cellular communication [5,6]. Alterations in the ECM is a
prominent feature in DN. Data from animal and in vitro studies
have demonstrated that TGF-b1 can up-regulate matrix protein
synthesis, and it plays a pivotal role in the hypertrophic and
fibrotic manifestations of DN [7–9]. Perlecan is a heparan sulfate
proteoglycan that maintains normal glomerular basement mem-
brane (GBM) structure [10,11], and is involved in the transport of
cells and small molecules across the GBM. Perlecan also binds
cytokines and growth factors through its glycosaminoglycan
chains, thereby acting as a reservoir for these peptides and
preventing them from being degraded. Perlecan is a major
contributor to the perm-selectivity of the GBM and a reduction of
these negatively charged macromolecules results in proteinuria
[12].
Mesangial cells constitute up to 40% of the total cells in the
glomerulus. They occupy a central position in the kidney where
they play a critical role in renal homeostasis and physiology, and
provide structural support to the glomerular capillary loops [13].
Mesangial cells are embedded in their own matrix, which they
synthesize and remodel. Qualitative and quantitative changes in
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the mesangial matrix will have a profound effect on mesangial cell
function.
Current treatment for DN, such as glycaemic and blood
pressure control and intervention of the renin-angiotensin pathway
using ACE inhibitors or angiotensin II receptor antagonists
[14,15], are at best partially effective. The majority of patients
progress on a relentless course of renal failure. The quest for new
treatments thus remains an unmet need. Sulodexide is a mixture of
glycosaminoglycans with 80% fast-moving heparin and 20%
dermatan sulfate [16,17]. It bears strong chemical similarities to
heparin but does not have anti-coagulation properties when given
orally. Treatment with sulodexide has been shown to reduce
proteinuria in patients with DN [18–20]. However, data from a
recent controlled trial showed negative results [21]. In the present
study, we investigated the effect of sulodexide on renal histopa-
thology and disease phenotype in a murine model of type I DN,
and its effects on fibrogenic processes in mesangial cells.
We demonstrated that sulodexide improved proteinuria and
renal function in mice with DN, which was associated with
increased perlecan expression along the GBM. Furthermore,
sulodexide selectively decreased renal expression of collagen type I
and IV, but increased glomerular expression of fibronectin and
collagen type III.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Institutional
Committee on the Use of Live Animals in Teaching and Research
at the University of Hong Kong.
Chemicals and Reagents
All chemicals and reagents were of the highest purity and
purchased from Sigma-Aldrich Chemical Company (Tin Hang
Technology Ltd, Hong Kong) unless otherwise stated. Antibodies
to perlecan, collagen type I, collagen type III, collagen type IV,
TGF-b1 and phosphorylated PKC-a and PKC-bI were purchased
from Santa Cruz Biotechnology Inc. (Genetimes Technology
International Holding Ltd, Hong Kong). Phosphorylated PKC-bII
and ERK were purchased from Cell Signaling Technology (Gene
Company, Hong Kong). Fibronectin antibody was purchased
from Sigma-Aldrich Chemical Company (Tin Hang Technology
Ltd, Hong Kong). QuantiChrom albumin, creatinine and urea
assay kits were purchased from BioAssay Systems (California,
USA). Accu-Chek Advantage II Glucostix test strips and Accu-
Chek Advantage blood glucose meter were purchased from Roche
Diagnostics (DKSH Hong Kong Ltd, Hong Kong). Sulodexide
(Vessel Due F) was purchased from Alfa Wassermann (Guangz-
hou, China).
Animal Studies
Male C57BL/6 mice at 6–8 weeks of age were purchased from
the Laboratory Animal Unit (University of Hong Kong, Hong
Kong) and received standard chow and water ad libitum. After one
week acclimatizing to their surroundings, mice were fasted for 6 h
prior to intra-peritoneal injection of streptozotocin (STZ, 50 mg/
kg) in 10 mM citrate buffer, pH 4.5, administered on five
consecutive days. Diabetes mellitus was confirmed by tail vein
blood sampling of glucose concentration, measured with Accu-
Chek Advantage II Glucostix test strips. Spot urine was tested
weekly for albuminuria with QuantiChrom albumin assay kit until
sacrifice. Mice with elevated blood glucose levels (.10 mM) and
albuminuria (.100 mg/dl) on two separate occasions two days
apart (defined as ‘baseline’ in the animal studies) were randomized
Figure 1. The effect of sulodexide on blood glucose, body
weight, and kidney weight-to-body weight ratio in control and
DN C57BL/6 mice. (A) Blood glucose level, (B) body weight and (C)
kidney weight-to-body weight ratio in control and DN mice treated
with saline or sulodexide are shown. Results are expressed as mean+SD
of data obtained from 6 mice per group. DN, diabetic nephropathy.
*P,0.001, with vs without DN for the same time-point.
doi:10.1371/journal.pone.0054501.g001
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to receive treatment with either saline (vehicle control) or
sulodexide (1 mg/kg/day) by oral gavage for 2, 4, 8 or 12 weeks
(6 mice per time-point for each group). After 2, 4, 8 and 12 weeks
of treatment, mice were sacrificed, blood samples were obtained
by cardiac puncture and the kidneys harvested, decapsulated and
weighed. The left kidney was cut perpendicular to the long-axis
and one half of the kidney was snap frozen in OCT followed by
immersion in liquid nitrogen, while the second half was fixed in
10% neutral-buffered formalin followed by paraffin embedding.
Renal cortical tissue from the right kidney was separated from the
medulla and frozen at 280uC until mRNA isolation. Six diabetic
mice that had just developed proteinuria were also sacrificed to
obtain baseline values for clinical, histological and morphometrical
parameters. Negative control groups included non-diabetic male
C57BL/6 mice treated with either saline or sulodexide for 12
weeks. Serum creatinine and urea levels were measured using
QuantiChrom creatinine and urea assay kits respectively.
Histological Assessment of the Kidney
Paraffin-embedded kidney sections (5 mm) were stained with
periodic acid-Schiff (PAS) and Masson’s trichrome for histologic
and morphometric analysis. Thirty cross-sectional profiles of PAS-
stained glomeruli were captured for each mouse. The glomerular
tuft area was determined using Axiovision 4.3 software (Zeiss,
Hong Kong). Assessment of mesangial matrix accumulation,
denoted by PAS-positive staining in nuclei-free areas of the
mesangium, was assessed in 30 randomly selected glomeruli and
scored in a blinded manner on a scale of 0 to 4, where 0 = 0–5%,
1= .5–25%, 2= .25–50%, 3= .50–75%, 4= .75%
deposition. The scores reflected variations in the extent rather
than intensity of staining, and the reproducibility of this scoring
system has been documented [22]. The ‘sclerotic index’ referred to
the mean score. Collagen deposition was assessed with Masson’s
trichrome staining of 30 glomeruli, scored in a blinded manner
using the aforementioned system and expressed as an arbitrary
unit (AU). Tubulo-interstitial changes such as collagen deposition,
tubular dilation and/or atrophy, and inflammatory cell infiltration
were assessed in 10 non-overlapping areas free of glomeruli, and
graded on a scale 1–4, where 0= normal, 0.5 = small focal areas
of damage, 1 = ,10%, 2= 10–25%, 3= 26–75% and 4= .75%
damage in the renal cortex [22] and expressed as mean tubulo-
interstitial score for each group.
Cytochemical Staining
Detection of phosphorylated ERK and PKC-a, TGF-b1,
fibronectin, and collagen type I, III and IV in paraffin-embedded
kidney sections (5 mm) from non-diabetic or DN mice treated with
saline or sulodexide was performed with specific antibodies
(dilution 1:50), followed by peroxidase-anti-peroxidase staining,
counterstained with hematoxylin and examined with an Axioskop
2 plus microscope as previously described [23,24]. Staining in the
capillary loops, mesangium and tubulo-interstitium was semi-
quantitatively assessed in at least 30 glomeruli and tubules per
mouse kidney, and the extent of staining graded as follows: 0 = 0–
5% staining, 1 = .5–25% staining, 2 = .25–50% staining, 3 =
.50–75% staining, 4 = .75% staining [22].
Immunohistochemical Analysis of Perlecan Expression
Snap frozen renal sections (8 mm) were blocked with 3% BSA in
PBS, incubated with rabbit anti-mouse perlecan antibody followed
by the appropriate secondary antibody in a darkened humidified
chamber. All incubation periods were 1 h at 37uC and sections
were washed thrice with PBS between steps. Sections were
mounted with fluorescent mountant and epifluorescence viewed
Figure 2. The effect of sulodexide on albuminuria and renal
function in control and DN C57BL/6 mice. (A) Urine albumin-to-
creatinine (ACR) ratio, (B) serum creatinine level and (C) serum urea level
in control and DN mice treated with saline or sulodexide are shown.
Results are expressed as mean+SD of data obtained from 6 mice per
group. Insert in (A) shows the effect of sulodexide on ACR in mice with
microalbuminuria (white circle) and macroalbuminuria (black circle)
with time. *P,0.01, **P,0.001, with vs without DN for the same time-
point, #P,0.01, DN baseline vs sulodexide-treated DN mice, 1P,0.001,
DN baseline vs saline-treated DN mice, {P,0.01, saline vs sulodexide
treatment for the same time-point.
doi:10.1371/journal.pone.0054501.g002
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Figure 3. The effect of sulodexide treatment on renal histology in control and DN C57BL/6 mice. (A) Representative images of PAS
stained renal specimens obtained from control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are shown. Mesangial
expansion, thickening of the Bowman’s capsule, and increased matrix accumulation are observed in DN mice and these changes are reduced in mice
treated with sulodexide, to levels similar to those observed in non-diabetic mice. Image-based computer assisted analysis was performed to semi-
quantify (B) glomerular sclerotic index as determined by the extent of PAS-positive staining and (C) surface area of the glomerular tuft. (D)
Representative images of renal sections stained for collagen deposition using Masson’s trichrome staining (depicted by the blue color). Asterisks
denote tubular atrophy. Image-based computer assisted analysis was performed to semi-quantify (E) the amount of collagen deposition in the
glomeruli and (F) tubulo-interstitial changes in control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group.
***P,0.001, DN mice vs non-diabetic mice for the same treatment at the same time-point, ###P,0.001, DN baseline vs non-diabetic baseline,
1P,0.05, 11P,0.01, 111P,0.001, compared to baseline for the same group, {{{P,0.001, saline vs sulodexide for the same time-point in DN mice.
Original magnification x1000 for panels (A) and (D).
doi:10.1371/journal.pone.0054501.g003
Figure 4. The effect of sulodexide on perlecan expression in renal tissue in control and DN C57BL/6 mice. (A) Gene expression of
perlecan core protein in control and DN mice treated with saline or sulodexide as determined by real-time PCR. (B) Representative images of perlecan
expression in snap frozen renal tissue from control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are shown.
Original magnification x1000. (C) Image-based computer assisted analysis was performed to semi-quantify the amount of perlecan in the glomeruli of
control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group. 111P,0.001, compared to baseline for the same
group, ###P,0.001, DN baseline vs non-diabetic baseline, ***P,0.001, DN mice vs non-diabetic mice for the same treatment, {{{P,0.001, saline vs
sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g004
Sulodexide and Diabetic Nephropathy
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using an Axioskop 2 plus fluorescent microscope. Images of 30
randomly selected glomeruli from control and treated mice were
captured and scored in a blinded manner as described above.
Quantitative Real-time Polymerase Chain Reaction for
TGF-b1, Fibronectin, Collagen Type I, III and IV, Perlecan
and Heparanase mRNA
RNA was isolated from snap frozen renal cortical tissue from
control and treated mice using AmbionH ToTALLY RNATM
Total RNA isolation kit according to the manufacturer’s
instructions. One microgram of total RNA was reverse transcribed
Figure 5. The effect of sulodexide on heparanase expression in renal tissue in control and DN C57BL/6 mice. (A) Gene expression of
heparanase in control and DN mice treated with saline or sulodexide as determined by real-time PCR. (B) Representative images of heparanase
protein expression in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are shown. Original magnification
x1000. Image-based computer assisted analysis was performed to semi-quantify the amount of heparanase in the (C) glomeruli and (D) tubulo-
interstitium of control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group. 1P,0.05, 11P,0.01, 111P,0.001,
compared to baseline for the same group, ##P,0.01, ###P,0.001, DN baseline vs non-diabetic baseline, ***P,0.001, DN mice vs non-diabetic mice
for the same treatment, {{P,0.01, {{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g005
Figure 6. The effect of sulodexide on phosphorylated PKC-a expression in the kidneys of control and DN C57BL/6 mice.
Representative images of (A) phosphorylated PKC-a in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are
shown. Original magnification x1000. Image-based computer assisted analysis was performed to semi-quantify the amount of phosphorylated PKC-a
in the (B) glomeruli and (C) tubulo-interstitium of control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group.
111P,0.001, compared to baseline for the same group, ###P,0.001, DN baseline vs non-diabetic baseline, ***P,0.001, DN mice vs non-diabetic mice
for the same treatment, {{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g006
Sulodexide and Diabetic Nephropathy
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to cDNA with M-MLV transcriptase using the random hexamers
method. Taqman quantitative real-time PCR reactions was
performed in duplicate using primer sets for TGF-b1, fibronectin,
collagen type I, collagen type III, collagen type IV, perlecan and
heparanase according to the manufacturer’s instructions (Assays-
on-Demand ID: Mm00441726_m1 for TGF-b1,
Mm00692666_m1 for fibronectin, Mm00801666_g1 for collagen
type I, Mm01254478_g1 for collagen type III, Mm01210125_m1
for collagen type IV, Mm01181165_m1 for perlecan and
Mm00461768_m1 for heparanase, Applied Biosystems, Hong
Kong) in a Lightcycler 480 II real-time PCR system. Comparative
real-time PCR results normalized to GAPDH were analyzed using
the Lightcycler 480 Software vs 1.5.0SP3 (Roche Diagnostics,
DKSH Hong Kong Limited, Hong Kong).
Culture of Murine Mesangial Cells (MMC)
MMC from BALB/c mice were obtained by differential sieving
of glomeruli and collagenase digestion. Cells were cultured in
RPMI 1640 medium containing 10% FCS and characterized by
their stellate morphology, ability to form hillocks, and immuno-
histochemical staining (positive for vimentin and negative for
cytokeratin and von Willebrand Factor). All experiments were
conducted on MMC of the 7–10th passage that had been growth
arrested for 72 h. MMC were pre-conditioned with 5 mM D-
glucose (physiological concentrations), 30 mM D-glucose or
Figure 7. The effect of sulodexide on phosphorylated ERK expression in the kidneys of control and DN C57BL/6 mice. Representative
images of (A) phosphorylated ERK in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are shown. Original
magnification x1000. Image-based computer assisted analysis was performed to semi-quantify the amount of phosphorylated ERK in the (B)
glomeruli and (C) tubulo-interstitium of control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group. 111P,0.001,
compared to baseline for the same group, ###P,0.001, DN baseline vs non-diabetic baseline, ***P,0.001, DN mice vs non-diabetic mice for the
same treatment, {P,0.05, {{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g007
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Figure 8. The effect of sulodexide on TGF-b1 gene and protein expression in renal tissue in control and DN C57BL/6 mice. (A) Gene
expression of TGF-b1 in control and DN mice treated with saline or sulodexide as determined by real-time PCR. (B) Representative images of TGF-b1
protein expression in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are shown. Original magnification
x1000. Image-based computer assisted analysis was performed to semi-quantify the amount of TGF-b1 in the (C) glomeruli and (D) tubulo-
interstitium of control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group. 1P,0.05, 11P,0.01, 111P,0.001,
compared to baseline for the same group, ###P,0.001, DN baseline vs non-diabetic baseline, *P,0.05, ***P,0.001, DN mice vs non-diabetic mice
for the same treatment, {{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g008
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Figure 9. The effect of sulodexide on collagen type I gene and protein expression in renal tissue in control and DN C57BL/6 mice.
(A) Gene expression of collagen type I (Coll I) in control and DN mice treated with saline or sulodexide as determined by real-time PCR. (B)
Representative images of collagen type I expression in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are
shown. Original magnification x1000. Image-based computer assisted analysis was performed to semi-quantify the amount of collagen type I in the
(C) glomeruli and (D) tubulo-interstitium of control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group.
1P,0.05, 11P,0.01, 111P,0.001, compared to baseline for the same group, #P,0.05, ###P,0.001, DN baseline vs non-diabetic baseline, ***P,0.001,
DN mice vs non-diabetic mice for the same treatment, {P,0.05, {{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g009
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Figure 10. The effect of sulodexide on collagen type IV gene and protein expression in renal tissue in control and DN C57BL/6 mice.
(A) Gene expression of collagen type IV (Coll IV) in control and DN mice treated with saline or sulodexide as determined by real-time PCR. (B)
Representative images of collagen type IV expression in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are
shown. Original magnification x1000. Image-based computer assisted analysis was performed to semi-quantify the amount of collagen type IV in the
(C) glomeruli and (D) tubulo-interstitium of control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group.
1P,0.05, 111P,0.001, compared to baseline for the same group, ###P,0.001, DN baseline vs non-diabetic baseline, **P,0.01, ***P,0.001, DN mice
vs non-diabetic mice for the same treatment, {{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g010
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Figure 11. The effect of sulodexide on collagen type III gene and protein expression in renal tissue in control and DN C57BL/6 mice.
(A) Gene expression of collagen type III (Coll III) in control and DN mice treated with saline or sulodexide as determined by real-time PCR. (B)
Representative images of collagen type III expression in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are
shown. Original magnification x1000. Boxed areas are enlarged to compare glomerular expression of collagen type III (depicted by arrows). Image-
based computer assisted analysis was performed to semi-quantify the amount of collagen type III in the (C) glomeruli and (D) tubulo-interstitium of
control and DN mice. Results are expressed as mean+SD of data obtained from 6 mice per group. 1P,0.05, 111P,0.001 compared to baseline for the
same group, ###P,0.001, DN baseline vs non-diabetic baseline, *P,0.05, **P,0.01, ***P,0.001, DN mice vs non-diabetic mice for the same
treatment, {{P,0.01, {{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g011
Sulodexide and Diabetic Nephropathy
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Figure 12. The effect of sulodexide on fibronectin gene and protein expression in renal tissue in control and DN C57BL/6 mice. (A)
Gene expression of fibronectin (FN) in control and DN mice treated with saline or sulodexide as determined by real-time PCR. (B) Representative
images of fibronectin expression in control and DN mice at baseline and after 12 weeks treatment with saline or sulodexide are shown. Original
magnification x1000. Boxed areas are enlarged to compare glomerular expression of fibronectin (depicted by arrows). Image-based computer
assisted analysis was performed to semi-quantify the amount of fibronectin in the (C) glomeruli and (D) tubulo-interstitium of control and DN mice.
Results are expressed as mean+SD of data obtained from 6 mice per group. 1P,0.05, 11P,0.01, 111P,0.001 compared to baseline for the same group,
###P,0.001, DN baseline vs non-diabetic baseline, **P,0.01, ***P,0.001, DN mice vs non-diabetic mice for the same treatment, {P,0.05, {{P,0.01,
{{{P,0.001, saline vs sulodexide treatment for the same time-point in DN mice.
doi:10.1371/journal.pone.0054501.g012
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Figure 13. The effect of Go¨6976, PD98059 and sulodexide on fibronectin and collagen type III synthesis and phosphorylation of
signaling pathways in murine mesangial cells. (A) Western blot analysis showing the effect of 5 mM D-glucose, 30 mM D-glucose and 30 mM
mannitol in the presence or absence Go¨6976 or PD98059 on fibronectin and collagen type III synthesis in murine mesangial cells after 24 h
incubation (upper panel). The intensity of the bands were analyzed by densitometric scan using ImageJ (NIH), normalized to b-actin and expressed as
arbitrary densitometric units (DU) (lower panels). ***P,0.001, 5 mM D-glucose vs 30 mM D-glucose, ###P,0.001, 30 mM D-glucose vs 30 mM
mannitol, 11P,0.01 or 111P,0.001, with vs without inhibitor for the same stimulation. (B) Western blot analysis showing the effect of 5 mM D-glucose,
30 mM D-glucose and 30 mM mannitol in the presence or absence of sulodexide on fibronectin and collagen type III synthesis in murine mesangial
cells after 24 h incubation. (C) Western blot analysis showing the effect of 5 mM D-glucose, 30 mM D-glucose and 30 mM mannitol in the presence
or absence of sulodexide on ERK PKC-a, PKC-bI or PKC-bII phosphorylation in murine mesangial cells after 24 h incubation.
doi:10.1371/journal.pone.0054501.g013
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30 mM mannitol (osmotic control) for 1 week before experiments.
Following pre-conditioning with glucose or mannitol, MMC were
cultured with 5 mM or 30 mM D-glucose, or 30 mM mannitol, in
the presence or absence of sulodexide (0–200 mg/ml) for 24 h, and
matrix protein synthesis and phosphorylation of ERK, PKC-a,
PKC-bI and PKC-bII were then investigated. Specific inhibitors
to PKC (Go¨6976, 10 mM) and ERK (PD98059, 50 mM) were used
to determine whether fibronectin and collagen type III synthesis
was mediated through PKC or ERK phosphorylation.
Western Blot Analysis
Whole cell lysates of MMC were obtained by solubilizing cells
cultured under control or experimental conditions in 20 mM
sodium acetate (pH 6.0) containing 4 M urea and 1% Triton X-
100 (200 ml). Aliquots of each cell lysate (10 mg total protein
content determined with a modified Lowry assay) were denatured
in sample buffer at 95uC for 5 min and subjected to SDS-PAGE.
Samples were electrophoresed on 8% acrylamide gels to investi-
gate fibronectin and collagen type I and III synthesis, and on 12%
acrylamide gels to investigate ERK, PKC-a, PKC-bI and PKC-
bII phosphorylation [24]. Proteins were transferred onto nitrocel-
lulose membranes using a mini-gel transfer system at 100 V for
1 h at 4uC. Equal loading of proteins was confirmed by staining
the membranes with Ponceau S solution. Membranes were
immunoblotted with primary antibodies to fibronectin, collagen
type III, b-actin, total and phosphorylated (phospho) ERK, PKC-
a, PKC-bI and PKC-bII, followed by the relevant horseradish
peroxidase-conjugated secondary antibodies as previously de-
scribed [25]. Bands were visualized by ECL and the band intensity
semi-quantitated by densitometry using ImageJ (NIH) software,
normalized to their respective house-keeping protein and ex-
pressed as arbitrary densitometric unit (DU). Fibronectin and
collagen type III were normalized to b-actin, and phospho-ERK,
phospho-PKC-a, phospho-PKC-bI and phospho-PKC-bII were
normalized to total ERK, PKC-a, PKC-bI and PKC-bII
respectively.
Statistical Analyses
Results are expressed as mean+SD. Statistical analysis was
performed using GraphPad Prism version 5.0 for Windows,
(GraphPad Software, San Diego, CA, USA). Differences were
assessed by ANOVA followed by Bonferroni’s multiple compar-
ison post-test. Two-tailed P,0.05 was considered statistically
significant.
Results
Persistent proteinuria accompanied by blood glucose level
above 30 mM was observed in 50% of male C57BL/6 mice 4–5
weeks after intra-peritoneal STZ administration. These mice were
then randomized to either saline or sulodexide treatment for
periods up to 12 weeks, with non-diabetic mice under same
treatments as negative controls.
Sulodexide Reduces Albuminuria and Renal Function
Deterioration in DN Mice
There was no difference in the survival of saline- or sulodexide-
treated DN or non-diabetic mice (data not shown). Elevated blood
glucose level remained stable over time in sulodexide-treated DN
mice, and was comparable to saline-treated controls (Figure 1A).
Sulodexide did not affect the blood glucose level in non-diabetic
mice. Mice with DN failed to gain weight, and their weight was
49.80% that of their non-diabetic counterpart after 12 weeks
(22.4363.32 and 44.6865.91 g respectively, P,0.001) (Figure 1B).
The kidney weight-to-body weight ratio was significantly higher in
DN mice compared with non-diabetic mice (1.1160.26% vs
0.4760.04% after 12 weeks, P,0.001) (Figure 1C). Sulodexide
Figure 14. Schematic diagram summarizing the pathways through which glomerulosclerosis and tubulo-interstitial fibrosis are
induced in C57BL/6 mice following streptozotocin administration and the differential effect of sulodexide on fibrotic processes.
doi:10.1371/journal.pone.0054501.g014
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treatment did not affect body weight or kidney weight-to-body
weight ratio (Figure 1B and C).
Urine albumin-to-creatinine ratio (ACR) increased over time in
DN mice (105.30651.47 vs 19.42612.65 g/mmol, 12 weeks vs
baseline, P,0.001), which was markedly reduced with sulodexide
treatment (Figure 2A). After 12 weeks of sulodexide treatment,
urine ACR was reduced by 53.86% compared with baseline
(P,0.01) and 91.40% compared with saline-treated DN mice
(P,0.001). The proteinuria reducing effect of sulodexide was
observed when baseline albuminuria was 100 mg/dl or above
300 mg/dl (Figure 2A). Serum creatinine and urea levels were
significantly higher in DN mice when albuminuria became
manifest compared with non-diabetic mice of the same age
(P,0.001). Both were significantly reduced after sulodexide
treatment (Figure 2B and C).
Effect of Sulodexide on Renal Histology
Glomerular abnormalities in DN mice were evident at the onset
of proteinuria, and became more severe over time. These included
increased glomerular surface area, mesangial expansion, thicken-
ing of the GBM and Bowman’s capsule, and increased deposition
of matrix proteins within the mesangial matrix (Figure 3A–E). The
‘sclerotic index’, which reflects glomerular matrix accumulation,
increased over time in saline-treated DN mice (3.4561.02 vs
1.8560.59, 12 weeks vs onset of albuminuria, P,0.001) (Figure 3A
and B), but was reduced with sulodexide treatment (2.1560.40
after 12 weeks) (P,0.001) (Figure 3B). The reduction in ‘sclerotic
index’ was accompanied by a significant reduction in glomerular
area (Figure 3A and C). Collagen deposition in the glomerulus was
markedly reduced following sulodexide treatment (Figure 3D and
E). Tubulo-interstitial changes such as tubular atrophy and
deposition of collagen in the interstitium were noted in saline-
treated mice after 12 weeks and were markedly reduced in
sulodexide-treated mice (Figure 3D and F).
Effect of Sulodexide on Perlecan and Heparanase
Expression in DN Mice
Perlecan is a heparan sulfate proteoglycan that plays a critical
role in the perm-selectivity of the GBM. Sulodexide treatment did
not affect perlecan mRNA or core protein expression in non-
diabetic mice (Figure 4A–C). Glomerular perlecan core protein
was markedly reduced in DN mice compared with non-diabetic
controls, and was partly restored after sulodexide treatment
(Figure 4A–C). Weak staining of perlecan was noted in the tubulo-
interstitial compartment of the kidney in control and sulodexide-
treated mice (Figure 4B).
Heparanase is increased in patients with DN, which degrade
heparan sulfate glycosaminoglycan chains thereby reducing the
electronegativity of the GBM and contributing to proteinuria [26].
DN mice showed a progressive increase in heparanase mRNA
level, which was 3.89-folds higher than that of non-diabetic
controls after 12 weeks (Figure 5A), and was accompanied by a
concomitant increase in heparanase protein expression in the
glomeruli and tubulo-interstitium (Figure 5B–D). Sulodexide
treatment significantly decreased heparanase mRNA in DN mice
to levels similarly observed in non-diabetic mice after 12 weeks
(Figure 5A), and this was associated with a decrease in heparanase
protein expression in both compartments of the kidney (Figure 5B–
D).
Effect of Sulodexide on PKC-a and ERK Phosphorylation
PKC-a and ERK phosphorylation are signaling pathways
involved in matrix protein accumulation in the kidney [27,28].
Sulodexide treatment did not affect PKC-a phosphorylation but
decreased ERK activation in non-diabetic mice (Figures 6 and 7).
PKC-a and ERK phosphorylation were increased in the tubulo-
interstitium in DN mice when proteinuria became manifest
(baseline), and continued to increase over time both in the
glomerular and the tubulo-interstitial compartment. Sulodexide
treatment reduced ERK phosphorylation in both compartments of
the kidney but only reduced tubulo-interstitial PKC-a phosphor-
ylation in DN mice (Figures 6 and 7).
Effect of Sulodexide on TGF-b1, Fibronectin and Collagen
Type I, III and IV Expression
DN mice showed higher TGF-b1 mRNA expression than non-
diabetic controls, and TGF-b1 protein expression was increased in
both the glomerular and tubulo-interstitial compartment of DN
mice (Figure 8). Sulodexide treatment did not affect TGF-b1
mRNA or protein expression in non-diabetic mice, but signifi-
cantly decreased TGF-b1 expression in DN mice (Figure 8A–D).
Similar findings were observed with collagen type I and IV mRNA
and protein expression (Figures 9 and 10).
DN mice showed increased collagen type III mRNA and
protein expression over time, with predominant expression
observed within the tubulo-interstitium (Figure 11A–D). Sulodex-
ide treatment reduced mRNA and tubulo-interstitial expression of
collagen type III, but markedly increased its expression in the
glomeruli (Figure 11A–D). Similar findings were also observed
with fibronectin mRNA and protein expression (Figure 12).
Collagen type III and fibronectin were weakly expressed in the
kidney of non-diabetic mice, their levels remained relatively stable
over time and were moderately increased following sulodexide
treatment.
Effect of Go¨6976, PD98059 and Sulodexide on
Fibronectin and Collagen Type III Synthesis and ERK, PKC-
a, PKC-bI and PKC-bII Phosphorylation in MMC
MMC constitutively synthesized fibronectin and minor amounts
of collagen type III in the presence of 5 mM D-glucose and their
levels were not altered when cells were cultured with 30 mM
mannitol. Thirty millimolar D-glucose significantly increased
fibronectin and collagen type III synthesis compared to 5 mM
D-glucose and 30 mM mannitol (Figure 13A). Inhibition of PKC
and ERK activation with Go¨6976 or PD98059 respectively
significantly reduced 30 mM D-glucose induced fibronectin
synthesis by 49.53% and 48.81% respectively (P,0.001 for both),
and collagen type III by 37.12% and 47.96% respectively (P,0.01
and P,0.001) (Figure 13A).
Under basal conditions, sulodexide increased constitutive
expression of fibronectin and collagen type III in a dose dependent
manner (fibronectin: 1.5260.56 vs 1.0060.00 DU, collagen type
III: 2.0160.75 vs 1.0060.00 DU, 200 mg/ml sulodexide vs no
sulodexide, P,0.01 for both), and similar results were also noted
when cells were cultured with sulodexide in the presence of
30 mM mannitol (Figure 13B). Concomitant incubation of MMC
with 30 mM D-glucose and sulodexide further increased fibro-
nectin and collagen type III synthesis in MMC (fibronectin:
4.0360.94 vs 1.2760.62 DU, collagen type III: 2.7160.82 vs
1.1060.39 DU, 200 mg/ml sulodexide vs no sulodexide, P,0.01
for both) (Figure 11B). ERK, PKC-a, PKC-bI and PKC-bII
phosphorylation were increased in cells cultured with 30 mM D-
glucose when compared to 5 mM D-glucose or 30 mM mannitol
(Figure 13C). Sulodexide decreased ERK and PKC-bII phos-
phorylation in a dose-dependent manner in control and 30 mM
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D-glucose stimulated cells but had no effect on PKC-a or PKC-bI
phosphorylation.
Discussion
In this study, C57BL/6 mice developed diabetes mellitus then
persistent proteinuria and impaired kidney function after STZ
administration. C57BL/6 mice with DN showed predominantly
glomerular lesions and proteinuria but relatively mild tubulo-
interstitial changes and our results are consistent with previous
studies [29,30]. Glomerular abnormalities included thickening of
the GBM, increased accumulation of fibrotic mediators in both the
glomerular and tubulo-interstitial compartments, reduced perle-
can expression and activation of signaling pathways.
A loss of heparan sulfate proteoglycans in the GBM contributes
to proteinuria in glomerular diseases including DN [11,31] and
quantitative and qualitative changes in the de novo synthesis of
heparan sulfate proteoglycan core protein and/or sulfation pattern
of the heparan sulfate glycosaminoglycan chains have been
proposed as pathogenic mechanisms [27,32]. In this study, we
demonstrated that perlecan core protein, to which the glycosami-
noglycan chains attach, was significantly reduced in the GBM of
DN mice despite perlecan mRNA stability. This would suggest
that changes to perlecan synthesis in renal cells exposed to elevated
glucose concentrations resulted from post-translational modifica-
tion, a finding that is consistent with previous studies [33,34].
Although we did not investigate changes to the heparan sulfate
glycosaminoglycan chains, given that synthesis of the protein core
precedes glycosaminoglycan chain synthesis, a reduction in
perlecan core protein expression would also suggest decreased
synthesis of heparan sulfate glycosaminoglycan chains and a
subsequent reduction in the perm-selectivity of the GBM. The
mechanism through which a loss of perlecan expression in the
GBM occurs in the setting of DN is currently unknown, but it is
possible that elevated glucose mediated induction of TGF-b1 bio-
activation may play an important role as observed in mesothelial
cells [35]. There is emerging evidence to suggest that reduced
intra-glomerular perlecan expression and subsequent albuminuria
in DN is also attributed to increased expression of heparanase, an
endo-b-D-glucuronidase that plays an important role in the
cleavage and degradation of heparan sulfate glycosaminoglycan
chains [36,37]. Glucose-mediated induction of PKC-a phosphor-
ylation has also been shown to play a causative role in the
progression of albuminuria since PKC-a deficient diabetic mice
showed diminished loss of perlecan expression and were protected
from the development of albuminuria [27]. In line with published
data, we have also demonstrated that progressive DN in C57BL/6
mice was associated with increased PKC-a activation and
heparanase expression that was associated with a concomitant
reduction in perlecan expression.
We demonstrated that at the time of established albuminuria,
TGF-b1 mRNA level in DN mice was significantly higher than
that detected in their age- and sex-matched non-diabetic
counterparts. TGF-b1 mRNA level gradually increased with
progressive disease manifestations, which paralleled increased
intra-renal TGF-b1 protein expression and matrix protein
deposition followed by renal fibrosis. Notably at study’s end,
mediators of fibrosis were also increased in non-diabetic mice
compared to baseline levels, suggesting that advancing age is also
associated with increased fibrogenesis.
Preventing the progression of DN and subsequent end-stage
renal failure are the fundamental aims in the management of DN.
Previous studies have demonstrated that sulodexide or its
constituents, namely heparin or dermatan sulfate, can reduce
albuminuria in diabetic patients [18,20,38,39], possibly through its
ability to restore heparan sulfate proteoglycans in the GBM,
inhibit heparanase and TGF-b1 activity, and reduce collagen type
IV deposition in the glomerulus [40–43]. Recent multicentre
studies however, have failed to reproduce the therapeutic effect of
sulodexide [21,44]. In these large multicentre studies, data from all
patients irrespective of race were pooled together and it is possible
that any beneficial effect of sulodexide treatment in certain sub-
populations may have been lost. Discrepancies between the earlier
studies and those of the recent multicentre studies may also be a
consequence of differences in treatment duration, recruitment of
type I or type II diabetic patients, severity of albuminuria when
patients started treatment, rate of absorption of sulodexide from
the gastrointestinal tract and drug formulation [44].
There are few mechanistic studies that have investigated the
effect of sulodexide on renal histology. We demonstrated a direct
and beneficial effect of sulodexide on various disease parameters
associated with DN without affecting blood glucose levels.
Sulodexide-treated DN mice demonstrated a reduction in
albuminuria, serum levels of urea and mesangial expansion that
was associated with increased perlecan expression, and down-
regulation of ERK phosphorylation, TGF-b1 and heparanase
expression, and collagen type I and IV deposition. Our results
showed that sulodexide treatment restored perlecan expression to
a level similar to that observed in non-diabetic mice. We
previously demonstrated that high glucose concentrations induced
TGF-b1 which in turn reduced the synthesis of perlecan core
protein and heparan sulfate glycosaminoglycan chains in human
peritoneal mesothelial cells [35]. These pathogenic mechanisms
may also apply in DN, as shown by the inverse relationship
between TGF-b1 and perlecan expression in our present study. A
reduction in TGF-b1 expression and the replenishment of
perlecan may have contributed to the improvement in albumin-
uria in DN mice following sulodexide treatment. Studies have
demonstrated that heparin can inhibit heparanase activity and
thus reduce heparan sulfate glycosaminoglycan chain degradation
in renal epithelial cells [37]. In this study, sulodexide was shown to
reduce heparanase mRNA transcript and protein expression in
DN mice to levels detected in non-diabetic mice, and this may
have also contributed to the improvement in albuminuria. In
addition to its role in the regulation of the perm-selectivity of the
GBM, perlecan has also been implicated in angiogenesis,
stabilization of the matrix scaffold, and sequestration of growth
factors such as FGF [45]. It is therefore possible that the
restoration of perlecan in the glomerulus of diabetic kidneys could
have various structural and functional benefits.
We demonstrated that sulodexide improved renal histology in
DN-treated mice, but further analysis revealed that the effect of
sulodexide on signaling pathway activation and matrix protein
synthesis was selective. Sulodexide effectively decreased ERK
activation and collagen type I and IV mRNA and protein
deposition in both glomerular and tubulo-interstitial compart-
ments of the kidney with time, whereas its beneficial effect on
PKC-a phosphorylation and collagen type III and fibronectin
deposition was only observed within the tubulo-interstitium.
Intriguingly, we noted that sulodexide markedly increased
glomerular expression of collagen type III and fibronectin in DN
mice despite a reduction in gene expression of these two matrix
proteins. This may be explained by the fact that cortical tissue was
used for our genetic studies, whereby the tissue comprised both
glomerular and tubulo-interstitial elements. Given that the tubulo-
interstitium occupies up to 90% of the total kidney volume, any
changes in collagen type III and fibronectin transcripts in the
glomerular compartment following sulodexide treatment may be
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masked by its effect on the tubulo-interstitium. Since TGF-b1
expression is reduced in DN mice following sulodexide treatment,
it is likely that sulodexide-mediated increase in collagen type III
and fibronectin expression is through a mechanism that is
independent of TGF-b1. Rossini et al demonstrated that sulodex-
ide could ameliorate early but not late stages of kidney disease in a
murine model of type II DN [46], but in contrast to our studies,
these researchers did not report any induction of matrix protein
synthesis by sulodexide. This anomaly may be due to different
pathogenic mechanisms induced in type I and II DN mouse
models and method of sulodexide administration. In a mild non-
hypertensive rat model of chronic kidney disease, sulodexide
improved renal function, although the beneficial effects of this
drug was not sustained [46], an observation that was also observed
in our study, whereby serum creatinine levels were reduced after 8
weeks treatment, but subsequently had no effect at later time-
points, possibly due to alterations in the structural integrity of the
glomerulus following drug treatment.
Although all resident renal cells participate in renal fibrosis, the
accumulation of matrix proteins within the glomerulus during
pathological conditions is initiated in the mesangium. Mesangial
cells were therefore utilized to investigate the effect of sulodexide
on matrix protein synthesis in vitro. We demonstrated that both
PKC and ERK signaling pathways regulated the synthesis of
matrix proteins in mesangial cells and reduced phosphorylation of
PKC isomers and ERK significantly decreased fibronectin and
collagen type III synthesis. Under our experimental setting, MMC
constitutively expressed phosphorylated ERK, PKC-a and PKC-
bII but not PKC-bI. Elevated glucose concentrations was shown
to increase ERK, PKC-a and PKC-bII phosphorylation and
induce PKC-bI activation in MMC. The effect of sulodexide on
PKC and ERK signaling pathways under physiological and
experimental conditions was selective, whereby sulodexide mark-
edly attenuated ERK and PKC-bII phosphorylation in control
and 30 mM D-glucose stimulated cells, but had no effect on PKC-
a or PKC-bI. These results corroborate our in vivo findings. The
role of PKC-bI in mediating fibrotic processes in the kidney is well
established [47–49]. Increased collagen type III and fibronectin
synthesis in MMC was observed following their exposure to
sulodexide, and their synthesis was further exacerbated by
sulodexide in the presence of elevated glucose concentration.
Based on these findings, it is plausible to suggest that the observed
increase in fibronectin and collagen type III expression in the
glomeruli of DN mice was directly attributed to the effect of
sulodexide on mesangial cells. A schematic diagram summarizing
our in vivo and in vitro data is shown in Figure 14.
In conclusion, we have demonstrated that sulodexide treatment
reduced albuminuria, improved serum levels of urea, restored
perlecan expression and ameliorated selective renal histopatho-
logic changes in male C57BL/6 DN mice that included reduced
collagen type I and IV deposition, and ERK and PKC-bII
activation. In contrast, sulodexide had no effect on PKC-a or
PKC-bI activation, but increased glomerular but not tubulo-
interstitial deposition of fibronectin and collagen type III. It is
possible that an increase in glomerular expression of these matrix
proteins and an inability to suppress PKC-a or PKC-bI activation
during progressive disease may explain at least in part, why
sulodexide showed no efficacy in recent clinical studies although
further studies are warranted to confirm this. Whether sulodexide
can provide renoprotection in sub-populations of DN patients with
specific histopathology remains to be determined.
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